Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $47
Veracyte, Inc.
Veracyte, Inc. VCYT | 0.00 |
Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:
VCYT) with a Underweight and raises the price target from $37 to $47.